[HTML][HTML] Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer
Assessment of programmed cell death-ligand 1 (PD-L1) expression by
immunohistochemistry (IHC) is the definite diagnostic test to guide treatment for patients with …
immunohistochemistry (IHC) is the definite diagnostic test to guide treatment for patients with …
PD-L1 assessment in lung cancer biopsies—pitfalls and limitations
D Gompelmann, P Sarova, B Mosleh… - The International …, 2024 - journals.sagepub.com
The programmed cell death-ligand 1 (PD-L1) protein expression on tumor cells predicts the
efficacy of immunotherapy in patients with non-small cell lung cancer. However, the …
efficacy of immunotherapy in patients with non-small cell lung cancer. However, the …
[HTML][HTML] PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer
Z Song, G Cheng, Y Zhang - Journal of Thoracic Disease, 2020 - ncbi.nlm.nih.gov
Background Programmed death ligand 1 (PD-L1) tumor proportion score (TPS) is currently
widely used for selection of immune therapies in non-small cell lung cancer (NSCLC). Most …
widely used for selection of immune therapies in non-small cell lung cancer (NSCLC). Most …
Predictive capability of PD-L1 protein expression for patients with advanced NSCLC: any differences based on histology?
N Meshulami, S Tavolacci, D de Miguel-Perez… - Clinical Lung Cancer, 2023 - Elsevier
Lung cancer is responsible for 1.8 million annual deaths. Non–small cell lung cancers
(NSCLC) represent 85% of lung cancer tumors. While surgery is an effective early-stage …
(NSCLC) represent 85% of lung cancer tumors. While surgery is an effective early-stage …
Programmed cell death ligand 1 immunohistochemistry: a concordance study between surgical specimen, biopsy, and tissue microarray
H Elfving, JSM Mattsson, C Lindskog, M Backman… - Clinical lung cancer, 2019 - Elsevier
Background The immunohistochemical analysis of programmed cell death ligand 1 (PD-L1)
expression in tumor tissue of non–small-cell lung cancer patients has now been integrated …
expression in tumor tissue of non–small-cell lung cancer patients has now been integrated …
[HTML][HTML] Cell block as a surrogate for programmed death-ligand 1 staining testing in patients of non-small cell lung cancer
Z Dong, Y Liu, T Jiang, L Hou, F Wu, G Gao, X Li… - Journal of …, 2020 - ncbi.nlm.nih.gov
Abstract Introduction: Programmed death-ligand 1 (PD-L1) staining is used in clinical
practice to guide the proper use of immune checkpoint inhibitors. This study aimed to …
practice to guide the proper use of immune checkpoint inhibitors. This study aimed to …
Biphasic prognostic significance of PD-L1 expression status in patients with early-and locally advanced-stage non-small cell lung cancer
K Teramoto, T Igarashi, Y Kataoka, M Ishida… - Cancer Immunology …, 2021 - Springer
Programmed cell death-ligand 1 (PD-L1) expression on tumor cells is induced by interferon-
gamma, suggesting the induction of an anti-tumor immune response. In turn, binding of PD …
gamma, suggesting the induction of an anti-tumor immune response. In turn, binding of PD …
[HTML][HTML] Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer
M Ilié, E Szafer-Glusman, V Hofman, E Chamorey… - Annals of …, 2018 - Elsevier
ABSTRACT Background Expression of PD-L1 in tumor cells and tumor-infiltrating immune
cells has been associated with improved efficacy to anti-PD-1/PD-L1 inhibitors in patients …
cells has been associated with improved efficacy to anti-PD-1/PD-L1 inhibitors in patients …
Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung …
Objective Accurate evaluation of tumor programmed death ligand 1 (PD-L1) expression can
assist in predicting whether a patient will respond to anti-PD-L1 therapy. In this study, we …
assist in predicting whether a patient will respond to anti-PD-L1 therapy. In this study, we …
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma
K Takada, T Okamoto, G Toyokawa, Y Kozuma… - Lung cancer, 2017 - Elsevier
Background Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)
pathway-targeted immunotherapy has become the standard option of care in the …
pathway-targeted immunotherapy has become the standard option of care in the …